Clinical and echocardiographic outcomes through 12-month follow-up of consecutive patients whounderwent MitraClip implantation were obtained from an ongoing prospective registry. Two different groups, dividedaccording to baseline echocardiographic criteria (investigational group [EVERESTOFF] and control group [EVERESTON]),were compared.RESULTSSeventy-eight patients were included in EVERESTOFFand 93 patients in EVERESTONgroups. Important andcomparable acute reductions in MR and no clip-related complications were revealed. The primary safety endpoint at30 days was comparable between groups (2.6% vs. 6.5%, respectively, p¼0.204); in addition, MR reduction wasmostly sustained, whereas equivalent improvement in New York Heart Association functional class were demonstrated.Kaplan-Meier freedom from death, surgery for mitral valve dysfunction, or grade$3þMR at 12 months was demon-strated in 71.4% and 76.2%, respectively, in the EVERESTOFFand EVERESTONgroups (log rank p¼0.378). Significantimprovements in ejection fraction and reduction in left ventricle volumes were demonstrated in both groups over time,but the baseline between-group differences were sustained.CONCLUSIONSMitraClip implantation in patients with expanded baseline echocardiographic features, comparedwith the control group, was associated with similar rates of safety and efficacy through 12-month follow-up. Furthervalidation of ourfindings is warranted. (J Am Coll Cardiol Intv 2015;8:74–82) © 2015 by the American College ofCardiology Foundation.From the *Division of Cardiology, Ferrarotto Hospital, University of Catania, Catania, Italy;yHarrington Heart and VascularInstitute, University Hospitals, Case Medical Center, Cleveland, Ohio;zInterventional Cardiology Department, PitangueirasHospital, Jundiai, São Paulo, Brazil;xDepartment of Cardiology, Tokai University School of Medicine, Isehara, Japan; and thekExcellence Through Newest Advances (ETNA) Foundation, Catania, Italy. Dr. Attizzani is a consultant with Medtronic; and hasreceived consulting fees from St. Jude Medical. Dr. Ohno is supported by a grant from the Japan Heart Foundation and BayerJACC: CARDIOVASCULAR INTERVENTIONSVOL.8,NO.1,2015ª2015 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATIONISSN 1936-8798/$36.00PUBLISHED BY ELSEVIER INC.http://dx.doi.org/10.1016/j.jcin.2014.07.024

Extended use of percutaneous edge-to-edge mitral valve repair beyond EVEREST (Endovascular Valve Edge-to-Edge Repair) criteria: 30-day and 12-month clinical and echocardiographic outcomes from the GRASP (Getting Reduction of Mitral Insufficiency by Percutaneous Clip Implantation) registry.

CAPODANNO, DAVIDE FRANCESCO MARIA;TAMBURINO, Corrado;Capranzano P;
2015-01-01

Abstract

Clinical and echocardiographic outcomes through 12-month follow-up of consecutive patients whounderwent MitraClip implantation were obtained from an ongoing prospective registry. Two different groups, dividedaccording to baseline echocardiographic criteria (investigational group [EVERESTOFF] and control group [EVERESTON]),were compared.RESULTSSeventy-eight patients were included in EVERESTOFFand 93 patients in EVERESTONgroups. Important andcomparable acute reductions in MR and no clip-related complications were revealed. The primary safety endpoint at30 days was comparable between groups (2.6% vs. 6.5%, respectively, p¼0.204); in addition, MR reduction wasmostly sustained, whereas equivalent improvement in New York Heart Association functional class were demonstrated.Kaplan-Meier freedom from death, surgery for mitral valve dysfunction, or grade$3þMR at 12 months was demon-strated in 71.4% and 76.2%, respectively, in the EVERESTOFFand EVERESTONgroups (log rank p¼0.378). Significantimprovements in ejection fraction and reduction in left ventricle volumes were demonstrated in both groups over time,but the baseline between-group differences were sustained.CONCLUSIONSMitraClip implantation in patients with expanded baseline echocardiographic features, comparedwith the control group, was associated with similar rates of safety and efficacy through 12-month follow-up. Furthervalidation of ourfindings is warranted. (J Am Coll Cardiol Intv 2015;8:74–82) © 2015 by the American College ofCardiology Foundation.From the *Division of Cardiology, Ferrarotto Hospital, University of Catania, Catania, Italy;yHarrington Heart and VascularInstitute, University Hospitals, Case Medical Center, Cleveland, Ohio;zInterventional Cardiology Department, PitangueirasHospital, Jundiai, São Paulo, Brazil;xDepartment of Cardiology, Tokai University School of Medicine, Isehara, Japan; and thekExcellence Through Newest Advances (ETNA) Foundation, Catania, Italy. Dr. Attizzani is a consultant with Medtronic; and hasreceived consulting fees from St. Jude Medical. Dr. Ohno is supported by a grant from the Japan Heart Foundation and BayerJACC: CARDIOVASCULAR INTERVENTIONSVOL.8,NO.1,2015ª2015 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATIONISSN 1936-8798/$36.00PUBLISHED BY ELSEVIER INC.http://dx.doi.org/10.1016/j.jcin.2014.07.024
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S1936879814015210-main.pdf

accesso aperto

Tipologia: Versione Editoriale (PDF)
Dimensione 772.79 kB
Formato Adobe PDF
772.79 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11769/44891
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 96
  • ???jsp.display-item.citation.isi??? 80
social impact